NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
Image
In a column published in Morning Consult, NPC Vice President of Research Michael Ciarametaro, MBA, and Senior Research Associate Brian Sils, MPP, explain why potential government involvement in drug pricing would be unlikely to increase patient affordability. In the commentary, they highlight a recent study from NPC and Xcenda and discuss the need to tackle affordability through benefit design to mitigate the cost-sharing responsibilities that insurance plans impose on patients.
Read the commentary in Morning Consult
Read about the NPC-Xcenda study
Learn more about the commentary authors.